Skip to content

Immunity After COVID-19 Vaccination

Estimation of Dynamics of Humoral Immunity in COVID-19 Vaccined Health Care Workers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04924855
Acronym
IACOVV
Enrollment
300
Registered
2021-06-14
Start date
2021-07-31
Completion date
2022-08-01
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tunis Military Hospital Staff Vaccinated Against Covid 19

Brief summary

The purpose of the research is to evaluate kinetic after vaccination to the COVID-19 coronavirus by measurements of specific and neutralizant antibodies for spike antigenic sequences . This work will allow us to follow the efficacy and tolerance of the vaccine over a year, to evaluate the antibody profile, their kinetics, the fraction of neutralising antibodies and will also allow us to understand the attitudes to be taken to ensure the best protection for our staff

Detailed description

Our objective is to follow the hospital staff after vaccination, for this we will include two groups of participants: G1: vaccinated staff who did not contract the virus (at the date of vaccination) and who had a serology \<0 at least at D7 of the date of vaccination dose 1 (known serological value) G2: vaccinated personnel who have contracted the virus with a PCR + and who have positive serology at least at D7 of the date of vaccination (known serological value)

Interventions

OTHERBlood sampling (4 per year)

Blood sampling (4 per year)

Sponsors

General Administration of Military Health, Tunisia
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

RB-approved informed consent, age 18 years or older, male or female, anyone considering COVID-19 vaccination or anyone that has received COVID-19 vaccination. Subjects can enroll at anytime after vaccination even though they may not have enrolled before vaccination. Sampling Frequency and timing: Up to 8 total samples in 12 months -

Exclusion criteria

Exclusion: Failure to provide informed consent \-

Design outcomes

Primary

MeasureTime frameDescription
Vaccine effectiveness1 yearVaccine effectiveness as measured by the number of positive PCRs in one year

Secondary

MeasureTime frameDescription
the tolerance of the vaccine1 yearpost-vaccination adverse event

Countries

Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026